Literature DB >> 24889928

Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo.

Dan Li1, Yingli Jin2, Ying Sun1, Jing Lei1, Chaoying Liu1.   

Abstract

Toll-like receptor 4 (TLR4)-mediated signaling has been implicated in tumor cell invasion, survival and metastasis in several types of cancers. However, the expression of TLR4 in patients with non-small cell lung cancer (NSCLC) and its biological function in the development and progression of NSCLC have not been elucidated to date. Here, we sought to characterize the expression of TLR4 in patients with NSCLC and to investigate the biological roles of TLR4 in lung metastasis, cell invasion and survival. In this study, we found that TLR4 expression was elevated in most patients with NSCLC, and its expression levels correlated with key pathological characteristics, including tumor differentiation, stage and metastasis. Our data also showed that downregulation of TLR4 expression using an RNA silencing approach in A549 tumor cells significantly suppressed cell proliferation, cell migration and cell invasion, and induced tumor apoptosis in vitro, and suppressed tumor growth in vivo. In addition, we also found that downregulation of TLR4 expression significantly decreased cell TNF-α and IL-6 levels. Furthermore, we found that knockdown of TLR4 was able to significantly suppress constitutive phosphorylation of Akt and PI3K, which may contribute to the inhibition of tumor growth. These data suggest that TLR4 plays an important role in tumorigenic properties of human NSCLC, and that RNA interference-directed targeting of TLR4 could be used as a potential anticancer therapeutic target in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24889928     DOI: 10.3892/ijo.2014.2479

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

1.  Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.

Authors:  Fengming Lan; Xiao Yue; Gang Ren; Yingjie Wang; Tingyi Xia
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

2.  Gram-negative bacteria facilitate tumor outgrowth and metastasis by promoting lipid synthesis in lung cancer patients.

Authors:  Maosong Ye; Xia Gu; Yang Han; Meiling Jin; Tao Ren
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 3.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

4.  Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling.

Authors:  Yiting Wang; Jing Cai; Xiaoli Zeng; Yajie Chen; Wei Yan; Yuming Ouyang; Dan Xiao; Zhiming Zeng; Long Huang; Anwen Liu
Journal:  BMC Cancer       Date:  2015-10-30       Impact factor: 4.430

5.  APRIL promotes non-small cell lung cancer growth and metastasis by targeting ERK1/2 signaling.

Authors:  Hengli Dou; Zhaohua Yan; Meng Zhang; Xiaoxin Xu
Journal:  Oncotarget       Date:  2017-11-27

6.  Roles of toll-like receptors: From inflammation to lung cancer progression.

Authors:  Jinjing Gu; Yi Liu; Bin Xie; Pingping Ye; Jiefan Huang; Zhe Lu
Journal:  Biomed Rep       Date:  2017-12-28

7.  Progress in the application and mechanism of metformin in treating non-small cell lung cancer.

Authors:  Chan Li; Yang Xue; Yu-Rong Xi; Ke Xie
Journal:  Oncol Lett       Date:  2017-03-14       Impact factor: 2.967

8.  Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.

Authors:  Kaiyuan Wang; Jian Wang; Feng Wei; Ning Zhao; Fan Yang; Xiubao Ren
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

9.  Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.

Authors:  Heikki Huhta; Olli Helminen; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen; Joonas H Kauppila
Journal:  Oncotarget       Date:  2016-04-26

10.  TLR4/ROS/miRNA-21 pathway underlies lipopolysaccharide instructed primary tumor outgrowth in lung cancer patients.

Authors:  Xianqi Zhang; Chunhong Wang; Shan Shan; Xiyu Liu; Zhongmin Jiang; Tao Ren
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.